Studieoverzicht

Study name: Tropion-Lung 08

Histology	NSCLC
Tumor stage	Stage IV
Host / recruiting sites	LUMC
Enrollment	Recruiting
Therapy line	First line (1L)
Design	Gerandomiseerde, fase 3 studie
Intervention	Dato-DXd (Datopotamab Deruxtecan) icm Pembrolizumab vs Pembrolizumab
Key outcome parameters	PFS, OS
Key inclusion criteria	Stadium IIIB-IV NSCLC zonder driver mutatie met PD-L1 ≥50%, geen eerdere systeemtherapie
Key exclusion criteria	Symptomatische CNS metastasen Co-morbiditeit oa LVEF <50%, ILD, equivalent >10mg prednison
Contact information	Log in voor de contactinformatie